http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104086627-B
Outgoing Links
Predicate | Object |
---|---|
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-04 |
filingDate | 2014-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2016-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2016-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-104086627-B |
titleOfInvention | There is the PD-L1 IgV affinity peptide S10 of anti-tumor activity |
abstract | The invention belongs to biological pharmacy technical field, does is it specifically related to a kind of targeting PD-L1 with anti-tumor activity? the affinity peptide S10 product of IgV and preparation thereof and application. Does this affinity peptide S10 specifically bind to PD-L1? IgV district, its aminoacid sequence is WSHGGHQHFIRF, and molecular weight is 1507.7. Affinity peptide S10 is prepared by Fomc solid phase polypeptide synthesis, plays a role as main active in preparing drugs against colon cancer. Is affinity peptide S10 provided by the present invention by utilizing phage display peptide library triage techniques, with PD-L1? IgV is that target spot carries out high flux screening acquisition. Do be inventor by lotus tumor experiment in Mice Body, it was demonstrated that affinity peptide S10 has good anti-tumor activity, can substantially suppress the growth of mouse interior tumor, thus being based on PD-L1? drug research and development new thinking and theoretical basis are provided. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IT-201800003470-A1 |
priorityDate | 2014-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 73.